D
Devonian Health Group Inc. (DVHGF)
OQB – Real Time Price. Currency in USD
5.69
-1.31 (-18.71%)
Market open: Sep 8, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
OQB – Real Time Price. Currency in USD
5.69
-1.31 (-18.71%)
Market open: Sep 8, 2026, 4:00 PM EDT
Devonian Health Group Inc. operates as a clinical stage biopharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs in Canada and Internationally. It engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops pantoprazole magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the purgenesis name. Devonian Health Group Inc. was founded in 2017 and is headquartered in Québec, Canada.
| Name | Position |
|---|---|
| Dr. Andre P. Boulet Ph.D. | Chair of the Board & CEO |
| Mr. Luc D. Gregoire CA, CPA | Executive Vice-President of Strategy |
| Date | Type | Document |
|---|---|---|
| 2026-07-27 | F-1 | tm2523460-26_f1.htm |